<DOC>
	<DOCNO>NCT01656668</DOCNO>
	<brief_summary>The purpose study investigate effect BC1036 ( theobromine ) cough-related quality life cough severity follow 2 week ' treatment .</brief_summary>
	<brief_title>Study Safety Effectiveness BC1036 Capsules Treat Frequent Long-Term Cough</brief_title>
	<detailed_description>Cough common disable symptom . At one time 20 % population troublesome cough sufferer consume 75 million dos over-the-counter anti-tussive ( anti-cough ) medication annually . Chronic cough presenting symptom almost respiratory conditions; also occur absence overt lung pathology . The study grade cough severity find 7 % general population cough sufficient interfere activity daily live least weekly basis UK . Cross sectional study consistently show chronic cough particularly prevalent middle age female . The investigational medicinal product BC1036 ( theobromine ) develop non-codeine , non-narcotic treatment persistent cough . Theobromine well characterise molecule long history safe use medicine food product . As member xanthine family , bear structural pharmacological similarity caffeine theophylline , long approve medicinal use . This placebo-controlled , double-blind , parallel group study BC1036 subject persistent cough ( chronic sub-acute ) , treatment resistant routine clinical assessment outline BTS Recommendations Management Cough Adults despite adequate treatment associate potential aggravating factor without continuance obvious precipitate factor . The objective investigate effect BC1036 cough-related quality life cough severity follow 2 week ' treatment . It plan recruit 288 evaluable subject cough clinic , secondary primary care centre UK . Subjects receive either BC1036 placebo period 14 day . Eligible subject require attend clinic five occasion : screening , baseline , day 7 , 14 , follow visit day 28 . At every visit subject complete Leicester Cough Questionnaire ( LCQ ) , cough Visual Analogue Score ( VAS ) . Spirometry perform measurement lung function . Blood sample draw safety clinical laboratory parameter physical examination ECG perform . Subjects see visit designate day ± 1 day , except Day 28 ± 2 day .</detailed_description>
	<mesh_term>Cough</mesh_term>
	<criteria>Male female age 18 75 year . Confirmed diagnosis persistent cough . Leicester Cough Questionnaire score ≤ 17 baseline . FEV ≥ 70 % predict normal , screen . See protocol Appendix 4 formula calculate predict value . Willing use effective contraception duration study . Female subject neither surgically sterilize postmenopausal ( defined menses one year FSH value &gt; 40 mIU/L ) require use two method throughout study 30 day . Besides abstinence follow contraceptive method acceptable : hormonal ( e.g . oral , injection , transdermal patch , implant , cervical ring ) , barrier ( e.g . condom diaphragm spermicidal agent ) intrauterine device . If hormonal contraceptive use must use 6 week first administration test product . Male subject must agree use condom duration study 30 day . Willing able give inform consent comply trial assessment trial procedure . Pregnant lactating female . Major surgery within 30 day precede screen visit . Any serious infection within 30 day prior screen visit . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , uncontrolled diabetes , renal hepatic disease psychiatric illness/social situation would limit compliance study requirement . Known hepatitis B C human immunodeficiency virus ( HIV ) syphilis seropositivity . A history serious adverse allergic reaction medication . Treatment another investigational medicinal product within 30 day prior enrollment . Treatment : Systemic oral steroid within 7 day prior randomisation Visit 2 . Theophylline theophyllinelike agent within 7 day prior randomisation . Opiates opioids e.g . codeine , dextromethorphan , within 7 day prior randomisation . ACE inhibitor within one month prior screen visit . Depot injection corticosteroid within 6 week screen visit . History suggestive febrile illness within last 7 day prior screen visit . Subjects significant sputum production ( defined 5 ml ( ~one teaspoon ) /day three day screen period ) . Current smoker past smoker smoke history &gt; 20 pack year stop smoke ≤ 12 month prior screen . Any pulmonary comorbidity COPD , recurrent low respiratory tract infection ( ≥ 2 12 month prior screen ) bronchiectasis cough suppression may lead sputum retention infection . Any pulmonary abnormality chest Xray CT scan perform twelve month prior enrolment indicative COPD , bronchiectasis etc . Subjects diagnose asthma suffer exacerbation require hospitalisation within 4 week prior screen . A history cancer within previous five year ( exclude carcinoma situ nonmelanoma skin cancer treat surgical excision ) . Uncontrolled hypertension ( rest systolic BP &gt; 170mmHg rest diastolic BP &gt; 95 mm Hg ) . A corrected QT interval &gt; 470ms female subject &gt; 450ms male subject , calculate use QTcF correction formula , second degree high heart block ECG recording , screen . Subjects know sensitivity methylxanthines related compound , know exhibit allergic response sensitivity cocoabased product . History presence alcohol substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Chronic</keyword>
	<keyword>Acute</keyword>
	<keyword>Persistent</keyword>
	<keyword>Longterm</keyword>
	<keyword>Cough</keyword>
</DOC>